↓ Skip to main content

A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice

Overview of attention for article published in Scientific Reports, June 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
5 Mendeley
Title
A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice
Published in
Scientific Reports, June 2016
DOI 10.1038/srep29131
Pubmed ID
Authors

Khamis Tomusange, Danushka Wijesundara, Jason Gummow, Tamsin Garrod, Yanrui Li, Lachlan Gray, Melissa Churchill, Branka Grubor-Bauk, Eric J. Gowans

Abstract

DNA vaccines are cost-effective to manufacture on a global scale and Tat-based DNA vaccines have yielded protective outcomes in preclinical and clinical models of human immunodeficiency virus (HIV), highlighting the potential of such vaccines. However, Tat-based DNA vaccines have been poorly immunogenic, and despite the administration of multiple doses and/or the addition of adjuvants, these vaccines are not in general use. In this study, we improved Tat immunogenicity by fusing it with the oligomerisation domain of a chimeric C4-binding protein (C4b-p), termed IMX313, resulting in Tat heptamerisation and linked Tat to the leader sequence of tissue plasminogen activator (TPA) to ensure that the bulk of heptamerised Tat is secreted. Mice vaccinated with secreted Tat fused to IMX313 (pVAX-sTat-IMX313) developed higher titres of Tat-specific serum IgG, mucosal sIgA and cell-mediated immune (CMI) responses, and showed superior control of EcoHIV infection, a surrogate murine HIV challenge model, compared with animals vaccinated with other test vaccines. Given the crucial contribution of Tat to HIV-1 pathogenesis and the precedent of Tat-based DNA vaccines in conferring some level of protection in animal models, we believe that the virologic control demonstrated with this novel multimerised Tat vaccine highlights the promise of this vaccine candidate for humans.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Professor 1 20%
Other 1 20%
Researcher 1 20%
Student > Doctoral Student 1 20%
Unspecified 1 20%
Other 0 0%
Readers by discipline Count As %
Immunology and Microbiology 3 60%
Unspecified 1 20%
Decision Sciences 1 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2017.
All research outputs
#6,848,408
of 8,987,048 outputs
Outputs from Scientific Reports
#30,991
of 43,317 outputs
Outputs of similar age
#220,188
of 309,257 outputs
Outputs of similar age from Scientific Reports
#2,411
of 3,283 outputs
Altmetric has tracked 8,987,048 research outputs across all sources so far. This one is in the 13th percentile – i.e., 13% of other outputs scored the same or lower than it.
So far Altmetric has tracked 43,317 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.0. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,257 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3,283 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.